FDA Approves Expanded Indication for Hyqvia to Treat Pediatric Primary Immunodeficiency
April 12th 2023During the 12-month trial period, Hyqvia was shown to be efficacious treating the occurrence of acute serious bacterial infections in children aged 2 through 16 years with primary immunodeficiency.
Read More
FDA Accepts Supplemental New Drug Application for Encorafenib, Binimetinib Combination in NSCLC
April 6th 2023The application is based on the PHAROS trial, which met its primary endpoint of objective response rate in patients with metastatic non–small cell lung cancer with a BRAF V600E mutation.
Read More
Expert: Diversity and Inclusion Efforts Must Move Beyond Passive Research to Action
March 24th 2023Presenter at the 2023 Community Oncology Alliance meeting notes that oncology has become more of a duality between molecular and genetic subsets, leading to huge developments in targeted and personalized care.
Read More
Immunotherapies, PARP Inhibitors Show Promise in Early Stage, Triple-Negative Breast Cancers
March 23rd 2023Drugs such as pembrolizumab, sacituzumab govitecan, and datopotamab deruxtecan all have growing bodies of evidence illustrating which patients with cancer are most likely to benefit and in which settings.
Read More
Durvalumab Improves Event-Free Survival in Resectable Non–Small Cell Lung Cancer
March 15th 2023Adding durvalumab to neoadjuvant chemotherapy to treat resectable early-stage non–small cell lung cancer did not increase complications and adverse events or comprise patients’ ability to undergo surgery versus chemotherapy alone.
Read More